Martin Wermke

FIND: a phase-II study to evaluate the efficacy and safety of erdafitinib in FGFR-altered NSCLC

Abstract Introduction: FGFR alterations occur in approximately 2% of non-small cell lung cancer (NSCLC) patients, predominantly in squamous cell histology (sqNSCLC). We evaluated the efficacy of the selective FGFR1-4 inhibitor erdafitinib in patients with FGFR-altered NSCLC. Meth...